Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Renovorx Inc (RNXT)

Renovorx Inc (RNXT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,148
  • Shares Outstanding, K 36,650
  • Annual Sales, $ 40 K
  • Annual Income, $ -8,810 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 1.31
  • Price/Sales 39.16
  • Price/Cash Flow N/A
  • Price/Book 4.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.08
  • Low Estimate -0.08
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7900 +41.77%
on 12/29/25
1.2500 -10.40%
on 01/09/26
+0.1600 (+16.67%)
since 12/09/25
3-Month
0.7006 +59.86%
on 11/14/25
1.3000 -13.85%
on 10/16/25
unch (unch)
since 10/09/25
52-Week
0.7006 +59.86%
on 11/14/25
1.6899 -33.72%
on 01/21/25
-0.2000 (-15.15%)
since 01/08/25

Most Recent Stories

More News
RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026

New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx’s TAMP Therapy Platform as a Targeted Drug-Delivery Approach Data Shows...

RNXT : 1.1200 (-2.61%)
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies...

RNXT : 1.1200 (-2.61%)
Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025

RALEIGH, NC / ACCESS Newswire / December 8, 2025 / iAccess Alpha's Virtual Best Ideas Winter Investment Conference will take place on December 9-10, 2025, bringing together top micro-cap companies and...

MOB : 7.81 (-4.05%)
BOSC : 4.91 (-3.73%)
STRT : 77.76 (+0.70%)
ELWT : 4.71 (-8.37%)
FLUX : 1.5900 (unch)
DGX.VN : 3.940 (+6.49%)
BCHT.TO : 5.70 (-0.87%)
GAME : 0.4700 (-0.11%)
WYY : 6.69 (+6.36%)
ACNT : 16.22 (-1.10%)
DCGO : 0.8941 (-1.22%)
VELO : 20.10 (-0.40%)
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

MOUNTAIN VIEW, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT)  (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies...

RNXT : 1.1200 (-2.61%)
iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025

RALEIGH, NC / ACCESS Newswire / December 1, 2025 / iAccess Alpha's Virtual Best Ideas Winter Investment Conference will take place on December 9-10, 2025, bringing together top micro-cap companies and...

MOB : 7.81 (-4.05%)
BOSC : 4.91 (-3.73%)
STRT : 77.76 (+0.70%)
ELWT : 4.71 (-8.37%)
DGX.VN : 3.940 (+6.49%)
BCHT.TO : 5.70 (-0.87%)
GAME : 0.4700 (-0.11%)
ACNT : 16.22 (-1.10%)
WYY : 6.69 (+6.36%)
DCGO : 0.8941 (-1.22%)
DGXX : 2.85 (+4.78%)
SCNX : 0.5601 (+1.34%)
RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th

MOUNTAIN VIEW, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT)  (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies...

RNXT : 1.1200 (-2.61%)
RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update

September 30, 2025 Cash and Cash Equivalents at $10 million Revenue Expected to Grow in 2026 and Continue to Offset Cash Burn Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN...

RNXT : 1.1200 (-2.61%)
RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th

MOUNTAIN VIEW, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies...

RNXT : 1.1200 (-2.61%)
RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

MOUNTAIN VIEW, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies...

RNXT : 1.1200 (-2.61%)
RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

MOUNTAIN VIEW, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies...

RNXT : 1.1200 (-2.61%)

Business Summary

RenovoRx Inc. is a biopharmaceutical company. It developed a therapy platform targeting difficult-to-treat tumors. RenovoRx Inc. is headquartered in Silicon Valley, California.

See More

Key Turning Points

3rd Resistance Point 1.3767
2nd Resistance Point 1.3133
1st Resistance Point 1.2167
Last Price 1.1200
1st Support Level 1.0567
2nd Support Level 0.9933
3rd Support Level 0.8967

See More

52-Week High 1.6899
Fibonacci 61.8% 1.3120
Fibonacci 50% 1.1953
Last Price 1.1200
Fibonacci 38.2% 1.0785
52-Week Low 0.7006

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar